Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)
NCT ID: NCT04402905
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
450 participants
OBSERVATIONAL
2020-06-15
2020-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If severe respiratory disease is the form that constitutes the extreme gravity of the disease (mortality, with more than 170,000 deaths worldwide to date).
However, there is a great heterogeneity of clinical forms with asymptomatic or symptomatic pauci forms, moderate forms, up to severe forms.
Different symptoms may appear: fever, cough, asthenia, dyspnea, gastrointestinal forms, anosmia and / or ageusia, skin involvement, etc.
Given the novelty of this infection, several questions remain:
* What are all the symptoms that can be contracted by a COVID-19 patient?
* Are there clinical forms not described?
* What is the evolutionary profile, the healing time of this disease in patients treated on an outpatient basis?
* What are the factors associated with a prolonged form of COVID-19 disease, including on an outpatient basis?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
International SARS-CoV-2 (COVID-19) Infection Observational Study
NCT04385251
Long-term Pulmonary Outcomes After Infection With Sars-CoV-2
NCT04401163
Observational Cohort of COVID-19 Patients at Raymond-Poincare
NCT04364698
The Natural History of Hospitalized COVID-19 Patients
NCT04424992
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
NCT04441372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Few data have been published on moderate forms, requiring no hospitalization, of strict outpatient management.
These so-called moderate forms, however, constitute the majority of cases of COVID-19 (approximately 80%).
In the Infectious and Tropical Diseases Department of Pitie Salpetriere, COVIDOM pilot site, at the beginning of March, during the intensification of the epidemic in France, a weekly telephone consultation was set up to take care of people tested for COVID + by PCR, or people not tested by PCR, or even tested with negative PCR but symptomatic and followed at home, suffering from moderate form of COVID-19, as well as their contact cases if they wished.
Telemedicine is particularly suitable in this epidemic context, ensuring continuity of care, while limiting face-to-face consultations, thus reducing the risk of cross-contamination.
Given the novelty of this infection, it is important to be able to best characterize these ambulatory forms, as well as their evolution, in order to manage these patients, and to offer primary care physicians a more detailed description of these forms. , which they are and will be called upon to take care of, general medicine being central to dealing with the epidemic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COVID PCR + patient: Patient screened positive by PCR on nasopharyngeal swab
* or COVID-like patient: Patient not screened, but considered COVID + because contact with a COVID PCR + person, and presenting symptoms suggestive of COVID-19 among:
* Influenza-like illness (fever, body aches, arthralgia, etc.)
* Respiratory form: dyspnea, cough, rhinitis
* Gastrointestinal form: diarrhea, nausea, vomiting
* Anosmia and / or ageusia
* or patient COVID PCR-: If patient tested negative by PCR on nasopharyngeal swab, but showing signs suggestive of COVID-19.
Exclusion Criteria
* Patient under justice or deprived of liberty.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine Katlama, MD
Role: PRINCIPAL_INVESTIGATOR
Pitie-Salpetriere Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yasmine Dudoit
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CREPATS 011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.